• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性心肌梗死中对链激酶的显性和亚临床反应。

Overt and subclinical reactions to streptokinase in acute myocardial infarction.

作者信息

Lynch M, Pentecost B L, Littler W A, Stockley R A

机构信息

General Hospital, Birmingham, United Kingdom.

出版信息

Am J Cardiol. 1994 Nov 1;74(9):849-52. doi: 10.1016/0002-9149(94)90574-6.

DOI:10.1016/0002-9149(94)90574-6
PMID:7977112
Abstract

The aims of this study were (1) to assess the possibility of predicting allergic reactions to streptokinase (SK) by measuring pretreatment antibody titers and by intradermal skin testing, and (2) to determine if SK is associated with subclinical changes in renal function. Specific anti-SK immunoglobulin G (IgG) and subclass IgG1 were assessed by enzyme-linked immunosorbent sorbent assays, and renal function was assessed by measurement of serum urea and creatinine in 204 patients with acute myocardial infarction. Twenty-six patients had 24-hour proteinuria loss and creatinine clearance assessed at presentation. Median IgG titer at presentation was 6 (range 0 to 10,000), and increased to 60 (range 0 to 18,000; p < 0.0001) on day 6. Fifteen of 180 patients (8.3%) had minor allergic reactions to SK; the median titer on admission for these patients was 5 (range 0 to 60), identical to those who tolerated SK uneventfully. No change was seen in serum urea or creatinine; for those treated with SK, the median value for proteinuria loss at day 0 was 0.45 g/liter (range 0.1 to 2), and decreased by day 5 to 0.1 g/liter (range 0.1 to 0.8; p = 0.0027). No significant proteinuria was seen in those who did not receive SK. The reactions to SK were minor, and could not be predicted on the basis of IgG titers at presentation. Significant proteinuria was found in the first 24 hours in SK-treated patients, but not in those who did not receive SK, and it resolved by day 5.

摘要

本研究的目的是

(1)通过测量治疗前抗体滴度和进行皮内皮肤试验来评估预测对链激酶(SK)过敏反应的可能性;(2)确定SK是否与肾功能的亚临床变化相关。通过酶联免疫吸附测定法评估特异性抗SK免疫球蛋白G(IgG)和IgG1亚类,通过测量204例急性心肌梗死患者的血清尿素和肌酐来评估肾功能。26例患者在就诊时评估了24小时蛋白尿丢失和肌酐清除率。就诊时IgG滴度中位数为6(范围0至10,000),第6天时升至60(范围0至18,000;p<0.0001)。180例患者中有15例(8.3%)对SK有轻微过敏反应;这些患者入院时的滴度中位数为5(范围0至60),与顺利耐受SK的患者相同。血清尿素或肌酐未见变化;接受SK治疗的患者,第0天蛋白尿丢失的中位数为0.45 g/升(范围0.1至2),到第5天时降至0.1 g/升(范围0.1至0.8;p = 0.0027)。未接受SK治疗的患者未见明显蛋白尿。对SK的反应轻微,无法根据就诊时的IgG滴度进行预测。SK治疗的患者在最初24小时内出现明显蛋白尿,但未接受SK治疗的患者未出现,且在第5天时消失。

相似文献

1
Overt and subclinical reactions to streptokinase in acute myocardial infarction.急性心肌梗死中对链激酶的显性和亚临床反应。
Am J Cardiol. 1994 Nov 1;74(9):849-52. doi: 10.1016/0002-9149(94)90574-6.
2
Thrombolytic treatment and proteinuria.溶栓治疗与蛋白尿
Br Heart J. 1995 Oct;74(4):354-7. doi: 10.1136/hrt.74.4.354.
3
Anaphylactic reactivity to streptokinase.对链激酶的过敏反应。
JAMA. 1984 Sep 14;252(10):1314-7.
4
Immunoglobulin response to intravenous streptokinase in acute myocardial infarction.急性心肌梗死患者对静脉注射链激酶的免疫球蛋白反应。
Br Heart J. 1991 Aug;66(2):139-42. doi: 10.1136/hrt.66.2.139.
5
[Anti-streptokinase antibodies].[抗链激酶抗体]
Arch Mal Coeur Vaiss. 1997 Jul;90(7):975-80.
6
[Anaphylactic reaction in streptokinase therapy].
Wien Klin Wochenschr. 1993;105(6):176-8.
7
Can anti-streptokinase antibody predict myocardial infarction outcomes after streptokinase treatment?抗链激酶抗体能否预测链激酶治疗后的心肌梗死结局?
J Pak Med Assoc. 2012 Mar;62(3 Suppl 2):S31-4.
8
Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).链激酶诱发的低血压对急性心肌梗死溶栓治疗的患者没有不利影响。罗马尼亚急性心肌梗死加速链激酶研究(ASK-ROMANIA)的一项子研究。
Rom J Intern Med. 2004;42(3):557-73.
9
Serum antibody titers in a systemic lytic therapy with streptokinase.
South Med J. 1998 Nov;91(11):1019-23. doi: 10.1097/00007611-199811000-00005.
10
Clinical usefulness of a functional test of neutralising streptokinase antibodies for the prediction of the thrombolytic effect of streptokinase in acute myocardial infarction.用于预测链激酶在急性心肌梗死中溶栓效果的中和链激酶抗体功能试验的临床实用性。
Cardiology. 2003;100(1):36-40. doi: 10.1159/000072390.

引用本文的文献

1
Fibrinolytics for the treatment of pulmonary embolism.纤维蛋白溶解剂治疗肺栓塞。
Transl Res. 2020 Nov;225:82-94. doi: 10.1016/j.trsl.2020.05.003. Epub 2020 May 17.
2
Profiling the immune responses of human patients treated with recombinant streptokinase after myocardial infarct.分析心肌梗死后接受重组链激酶治疗的人类患者的免疫反应。
Mol Divers. 2004;8(3):251-6. doi: 10.1023/b:modi.0000036235.45565.50.
3
Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?
Drugs Aging. 1995 Aug;7(2):110-6. doi: 10.2165/00002512-199507020-00005.
4
Thrombolytic treatment and proteinuria.溶栓治疗与蛋白尿
Br Heart J. 1995 Oct;74(4):354-7. doi: 10.1136/hrt.74.4.354.